Objective Short-acting β2-agonist (SABA) over-reliance is associated with poor asthma
outcomes. As part of the SABA Use IN Asthma (SABINA) III study, we assessed SABA …

Background The extent of short-acting β2-agonist (SABA) overuse in Africa remains poorly
documented. As part of the SABA use IN Asthma (SABINA) III study, we assessed SABA …

Background To gain a global perspective on short-acting β2-agonist (SABA) prescriptions
and associated asthma-related clinical outcomes in patients with asthma, we assessed …

Objective Short-acting β2-agonist (SABA) overuse is associated with poor asthma outcomes;
however, the extent of SABA use in Thailand is largely unknown. As part of the SABA use IN …

Background Over-reliance on short-acting β2-agonists (SABAs) is associated with poor
asthma outcomes. However, the extent of SABA use in Turkey is unclear owing to a lack of …

Background Although short-acting β2-agonist (SABA) overuse is associated with poor
treatment outcomes, data on SABA use in the Middle East are lacking. Research design and …

Background Despite a clear guideline for asthma medication, excessive use of short-acting
β2-agonists (SABAs) is common in clinical practice. Previous research has shown that …

Background The overuse of short-acting β2-agonists (SABA) is associated with poor asthma
control. However, data on SABA use in the Gulf region are limited. Herein, we describe …

Abstract Short-acting β2-agonist (SABA) prescriptions and associated outcomes were
assessed in 1440 patients with asthma from the SABA use IN Asthma (SABINA) III study …

Background The extent of short-acting Beta-2-agonist (β 2-agonist)(SABA) use across Asian
countries is not well documented. As part of the SABA use IN Asthma (SABINA) III study, we …